Hans J Hammers Selected Research

Margins of Excision

1/2020

Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hans J Hammers Research Topics

Disease

38	Renal Cell Carcinoma (Grawitz Tumor) 04/2024 - 06/2010
21	Neoplasms (Cancer) 04/2024 - 01/2004
6	Neoplasm Metastasis (Metastasis) 01/2021 - 06/2010
4	Kidney Neoplasms (Kidney Cancer) 01/2021 - 01/2020
4	Fatigue 01/2020 - 11/2015
2	Hypertension (High Blood Pressure) 10/2019 - 07/2016
2	Body Weight (Weight, Body) 04/2018 - 11/2015
2	Disease Progression 01/2017 - 07/2016
2	Prostatic Neoplasms (Prostate Cancer) 10/2015 - 08/2014
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024
1	Exanthema (Rash) 01/2024
1	Neutropenia 01/2024
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2022
1	Colitis 01/2022
1	Margins of Excision 01/2020
1	Stomatitis 01/2020
1	Pruritus (Itching) 01/2020
1	Dyspnea (Shortness of Breath) 10/2018
1	Nausea 10/2018
1	Diarrhea 10/2018
1	Melanoma (Melanoma, Malignant) 12/2017
1	Adenocarcinoma 12/2017
1	Carcinoma (Carcinomatosis) 12/2017
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 12/2017
1	Paraganglioma (Paragangliomas) 12/2017
1	Pheochromocytoma 12/2017
1	Adrenocortical Carcinoma 12/2017
1	Arthritis (Polyarthritis) 01/2017
1	Aspergillosis 07/2016
1	Aspiration Pneumonia 07/2016
1	Anemia 11/2015

Drug/Important Bio-Agent (IBA)

22	NivolumabIBA 01/2024 - 05/2015
15	Immune Checkpoint InhibitorsIBA 04/2024 - 09/2016
11	Sunitinib (Sutent)FDA Link 01/2022 - 06/2010
11	IpilimumabIBA 01/2022 - 12/2017
6	Everolimus FDA Link 01/2020 - 11/2015
3	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2021
3	pazopanib FDA Link 03/2019 - 12/2017
3	Tyrosine Kinase InhibitorsIBA 12/2017 - 06/2010
2	cabozantinibIBA 10/2018 - 07/2016
2	Interleukin-2 (IL2)IBA 12/2017 - 12/2017
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2013 - 06/2010
1	PentosesIBA 04/2024
1	Fatty Acids (Saturated Fatty Acids)IBA 04/2024
1	Phosphates (Orthophosphate)IBA 04/2024
1	Epidermal Growth Factor (EGF)IBA 01/2024
1	B7-H1 AntigenIBA 01/2022
1	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2022
1	Proton Pump InhibitorsIBA 01/2022
1	Lipase (Acid Lipase)FDA Link 10/2019
1	Amylases FDA Link 10/2019
1	Alanine Transaminase (SGPT)IBA 10/2019
1	atezolizumabIBA 01/2019
1	Bevacizumab (Avastin)FDA Link 01/2019
1	4-carboxyphenylglyoxalIBA 12/2017
1	entinostat (MS 275)IBA 12/2017
1	Histone Deacetylase InhibitorsIBA 12/2017
1	tributyl phosphate (TBP)IBA 01/2017
1	Circulating Tumor DNAIBA 10/2016
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2016
1	AntigensIBA 01/2016
1	TabletsIBA 11/2015
1	QuercetinIBA 10/2015
1	Ellagic AcidIBA 10/2015
1	AndrogensIBA 10/2015
1	ResveratrolIBA 10/2015
1	Immunoglobulins (Immunoglobulin)IBA 06/2015
1	Prostate-Specific Antigen (Semenogelase)IBA 08/2014
1	orteronelIBA 08/2014
1	SteroidsIBA 08/2014
1	AnticoagulantsIBA 05/2004
1	matrigelIBA 05/2004
1	lipoprotein-associated coagulation inhibitor (TFPI)IBA 05/2004
1	Peptides (Polypeptides)IBA 05/2004
1	VLDL receptorIBA 05/2004
1	withaferin AIBA 01/2004

Therapy/Procedure

17	Therapeutics 01/2022 - 06/2010
6	Immunotherapy 04/2024 - 01/2019
3	Nephrectomy 01/2024 - 12/2019
1	Drug Therapy (Chemotherapy) 01/2024
1	Duration of Therapy 01/2020
1	Length of Stay 01/2020
1	Metastasectomy 12/2019
1	Immunomodulation 12/2017
1	Castration 08/2014